Cargando…

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase

Letrozole is a commonly used treatment option for metastatic hormone receptor-positive (HR+) breast cancer, but many patients ultimately relapse. Due to the importance of phosphoinositide-3 kinase (PI3K) in breast cancer, PI3K inhibitors such as taselisib are attractive for combination with endocrin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoeflich, Klaus P., Guan, Jane, Edgar, Kyle A., O'Brien, Carol, Savage, Heidi, Wilson, Timothy R., Neve, Richard M., Friedman, Lori S., Wallin, Jeffrey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918946/ https://www.ncbi.nlm.nih.gov/pubmed/27382432 http://dx.doi.org/10.18632/genesandcancer.100

Ejemplares similares

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway
por: Wang, Shunde, et al.
Publicado: (2018)

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes
por: Wallin, Jeffrey J., et al.
Publicado: (2012)

Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
por: Balakrishnan, A, et al.
Publicado: (2011)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
por: Rezaei, Ako, et al.
Publicado: (2022)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
por: De Luca, Michele, et al.
Publicado: (2022)

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer
por: Tamura, Kenji, et al.
Publicado: (2018)

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition
por: Edgar, Kyle A., et al.
Publicado: (2014)

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer
por: Colomer, R, et al.
Publicado: (2005)

Evaluation of Different Doses of the Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy and Its Effect on Villous Trophoblastic Tissue
por: Alabiad, Mohamed Ali, et al.
Publicado: (2022)

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
por: Miller, William R, et al.
Publicado: (2010)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016)

Kelulut Honey Improves Folliculogenesis, Steroidogenic, and Aromatase Enzyme Profiles and Ovarian Histomorphology in Letrozole-Induced Polycystic Ovary Syndrome Rats
por: Kamal, Datu Agasi Mohd, et al.
Publicado: (2022)

Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
por: Edris, Alaa, et al.
Publicado: (2023)

The effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization
por: Lee, Kyung-Hee, et al.
Publicado: (2014)

Morphological and Functional Changes in Skin of Adult Male Rats Chronically Treated with Letrozole, a Nonsteroidal Inhibitor of Cytochrome P450 Aromatase
por: Misiakiewicz-Has, Kamila, et al.
Publicado: (2020)

Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats
por: Shaaban, Zahra, et al.
Publicado: (2022)

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells
por: Abrhale, Tesfom, et al.
Publicado: (2011)

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
por: Garcia-Casado, Zaida, et al.
Publicado: (2010)

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
por: HOLE, STINE, et al.
Publicado: (2015)

Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel–Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study
por: Luu, M., et al.
Publicado: (2021)

The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer
por: Lisztwan, Joanna, et al.
Publicado: (2008)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019)

The early days of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2007)

The early days of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2008)

Letrozole for Female Infertility
por: Yang, Ai-Min, et al.
Publicado: (2021)

SAT-101 The Booster Effect of Aromatase Inhibitor to Overcome Waning Effect of Recombinant Human Growth Hormone
por: Kim, Dae Hyun, et al.
Publicado: (2020)

The discovery and mechanism of action of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007)

An Effect of Letrozole on Gastric Cancer?
por: EL Hadi, Ahmed, et al.
Publicado: (2011)

The discovery and mechanism of action of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008)

Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome
por: Hajishafiha, Masomeh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hb4c8d1gqd9ib04sk7vhr3ag5g